Ob­sE­va high­lights a pos­i­tive da­ta point from its PhI­II study of new fer­til­i­ty drug, beats a path to reg­u­la­tors

Ob­sE­va $OB­SV re­port­ed that its late-stage tri­al of their lead ther­a­py aimed at pro­mot­ing preg­nan­cies among women with low fer­til­i­ty came through with a boost in the rate of women who were ex­pect­ing a child in Phase III.

The late-stage da­ta were mixed, but the biotech was able to pin­point a group of women with a sta­tis­ti­cal­ly sig­nif­i­cant in­crease in preg­nan­cies com­pared to a place­bo. Now the Swiss biotech will set out to get some reg­u­la­to­ry feed­back on what they need to do to get an ap­proval as they con­tin­ue to fol­low these women through births and the in­fan­cy of their new­borns. And in­vestors can de­bate whether a mar­gin­al boost in preg­nan­cies is enough to war­rant an ap­proval — or much of a mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER